Onken et al
1report a prospective evaluation of a gene expression profiling (GEP)-based assay, designed around 15 genes, that assigns uveal melanoma (UM) to 2 prognostic subgroups: Classes 1 and 2, which respectively are associated with low and high risks of metastasis. In 260 UM patients, they compared GEP with detection of chromosome 3 loss of heterozygosity using a single nucleotide polymorphism (SNP) assay, stating that GEP is better at predicting metastatic risk. They also claim that GEP is more accurate than other cytogenetic- or molecular methods, which they dismiss as ‘not suitable for routine clinical use.' In our opinion, the authors' claims and criticisms are not founded on adequate scientific data.
- Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma.Ophthalmology. 2012; 119: 1596-1603
- Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma.Clin Cancer Res. 2007; 13: 2923-2927
- Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification.Clin Cancer Res. 2010; 16: 6083-6092
- Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival.Am J Pathol. 2013; 182: 678-687
- Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis.IJBET. 2012; 8: 18-35
© 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.